Item 2.02 Results of Operations and Financial Condition

On March 13, 2013, Sucampo Pharmaceuticals, Inc. ("the Company") announced its consolidated financial results for the fourth quarter and year ended December 31, 2012. The full text of the press release issued in connection with the announcement was furnished as Exhibit 99.1 to the Current Report on Form 8-K and is incorporated herein by reference. The slides from the presentation and the transcript of the webcast attached as Exhibits 99.2 and 99.3 to the Form 8-K as well as the disclosure under Item 7 are incorporated herein by reference.

The information in this Form 8-K/A shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 7.01. Regulation FD Disclosure.

On March 13, 2013, the Company hosted a conference call with investors to discuss the Company's financial and operating results for the fourth quarter and fiscal year 2012 ended December 31, 2012. The conference call including slides were made available to the public via conference call and webcast. The slides from the presentation were furnished as Exhibit 99.2 and the transcript was furnished as Exhibit 99.3 to the Form 8-K and are both incorporated herein by reference.

The information in this Item 7.01 and Exhibits 99.2 and 99.3 to this Form 8-K/A shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

---